Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionVontobel Holding Ltd.
Latest Disclosed Ownership2,828 shares
Latest Disclosed Value $ 372,561
Vontobel Holding Ltd. reports 3.89% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 8, 2026 - Vontobel Holding Ltd. filed a 13F-HR form disclosing ownership of 2,828 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $372,561 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 2,722 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 3.89% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,828 106 3.89 373 -3.63 0.0013
2026-02-13 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,722 -13 -0.48 386 0.78 0.0012
2025-10-15 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,735 -1,376 -33.47 384 -25.78 0.0012
2025-07-23 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,111 -5,832 -58.65 517 -53.05 0.0016
2025-04-28 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,943 1,501 17.78 1,100 -4.60 0.0040
2025-01-30 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,442 -6,148 -42.14 1,152 -31.47 0.0039
2024-10-16 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,590 1,639 12.66 1,681 -5.67 0.0054
2024-08-13 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,951 4,801 58.91 1,783 58.54 0.0058
2024-05-10 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,150 2,061 33.85 1,124 40.15 0.0090
2024-06-04 2023-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 6,089 -2,369 -28.01 802 -15.67 0.0067
2024-01-30 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,564 -2,617 997 0.0050
2024-06-04 2023-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 8,458 -1,250 -12.88 952 3.93 0.0088
2023-10-11 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,181 -1,250 1,145 0.0064
2024-06-04 2023-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 9,708 -595 -5.78 915 -12.19 0.0080
2023-07-24 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,431 1,128 1,078 0.0057
2024-06-04 2023-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 10,303 7,082 219.87 1,043 172.77 0.0097
2023-04-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,026 8,805 1,217 0.0069
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,221 -2,644 -45.08 382 -36.65 0.0039
2022-11-04 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,865 959 19.55 603 25.10 0.0070
2022-07-27 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,906 -35,189 -87.76 482 -87.00 0.0052
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,095 18,222 83.31 3,707 100.27 0.0320
2022-02-14 2021-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 21,873 3,890 21.63 1,851 7.37 0.0154
2022-02-10 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,983 0 1,724 0.0065
2021-10-29 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,983 -1,386 -7.16 1,724 -8.15 0.0152
2021-08-06 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,369 3,374 21.09 1,877 20.63 0.0162
2021-05-11 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,995 -2,858 -15.16 1,556 -29.85 0.0115
2021-02-12 2020-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 18,853 18,853 2,218 0.0145
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,853 2,218 0.0145
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.